Kunisada Toshiyuki, Nakata Eiji, Fujiwara Tomohiro, Katayama Haruyoshi, Itano Takuto, Kurozumi Takanao, Ando Teruhiko, Ozaki Toshifumi
Department of Orthopaedic Surgery, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Okayama 700-8558, Japan.
Department of Medical Materials for Musculoskeletal Reconstruction, Okayama University Graduate School of Medicine, Dentistry, and Pharmaceutical Sciences, 2-5-1, Shikata-cho, Okayama 700-8558, Japan.
Biomimetics (Basel). 2025 Feb 10;10(2):101. doi: 10.3390/biomimetics10020101.
The purpose of this study was to evaluate radiographic changes, clinical outcomes, and complications following unidirectional porous beta-tricalcium phosphate (UDPTCP) implantation for the treatment of benign bone tumors. We retrospectively analyzed 46 patients who underwent intralesional resection. The patients were divided into two cohorts: Cohort 1 (n = 32), which included all bones except the phalanges and metacarpal/tarsal bones, and Cohort 2 (n = 14), which included the phalanges and metacarpal/tarsal bones. Radiographic changes were assessed at each reading based on resorption of the implanted UDPTCP and bone trabeculation through the defect. UDPTCP resorption and bone trabeculation were observed on radiographs within 3 months of surgery in all patients. Bone remodeling in the cavity progressed steadily for up to 3 years postoperatively. In Cohort 1, resorption and trabeculation progressed significantly in young patients, and trabeculation developed significantly in small lesions. The rates of resorption and trabeculation at 3 months postoperatively correlated statistically with their increased rates at one year. There was no statistical difference in resorption and trabeculation rates between Cohort 1 and Cohort 2. There were no cases of postoperative deep infections or allergic reactions related to the implant. UDPTCP is a useful bone-filling substitute for the treatment of benign bone tumors and has a low complication rate.
本研究的目的是评估单向多孔β-磷酸三钙（UDPTCP）植入治疗良性骨肿瘤后的影像学变化、临床结果及并发症。我们回顾性分析了46例行病灶内切除术的患者。患者被分为两个队列：队列1（n = 32），包括除指骨和掌骨/跗骨以外的所有骨骼；队列2（n = 14），包括指骨和掌骨/跗骨。每次读片时根据植入的UDPTCP的吸收情况以及通过缺损处的骨小梁形成情况评估影像学变化。所有患者在术后3个月内的X线片上均观察到UDPTCP吸收和骨小梁形成。术后长达3年，腔内骨重塑稳定进展。在队列1中，年轻患者的吸收和骨小梁形成进展显著，小病灶中骨小梁形成显著。术后3个月时的吸收和骨小梁形成率与1年时的增加率具有统计学相关性。队列1和队列2之间的吸收和骨小梁形成率无统计学差异。没有与植入物相关的术后深部感染或过敏反应病例。UDPTCP是治疗良性骨肿瘤的一种有用的骨填充替代物，并发症发生率低。
